



medicines
patent
pool



THE MEDICINES PATENT POOL
EXPANDING ACCESS TO PUBLIC HEALTH

Mission

Increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through voluntary licensing and patent pooling.

We work with a range of partners — civil society, international organisations, industry, patient groups and governments — to prioritise and license novel and existing medicines and health technologies for people in these countries.

Vision

A world in which people in need in LMICs have rapid access to effective and affordable medical treatments and health technologies.

PATENT HOLDERS

Effective and impactful way to make available innovative products in resource-limited settings; licence management; reduced distribution costs

LOW-COST PRODUCERS

Accelerated approach to the development of affordable versions of existing medicines, creation of formulations and fixed-dose if needed new combinations

GOVERNMENTS, TREATMENT PROVIDERS

Ability to stretch budgets to treat more people with WHO-recommended medicines

COMMUNITIES

Greater access to quality, appropriate, affordable and life-saving treatments







<p>lopinavir ritonavir (adults)</p> <p>lopinavir ritonavir (paediatrics)</p>	<p>nevirapine (non-assert)</p>	<p>atazanavir</p>	<p>bictegravir cobicistat elvitegravir emtricitabine tenofovir alafenamide tenofivir disoproxil</p>	<p>darunavir (paediatric; non-assert)</p>	<p>raltegravir (paediatric)</p>	<p>darunavir related</p>
--	------------------------------------	-------------------	---	---	-------------------------------------	------------------------------



<p>abacavir (paediatrics)</p> <p>dolutegravir (paediatrics)</p> <p>dolutegravir (adults)</p>	<p>valganciclovir (pricing agreement)</p>	<p>solid drug nanoparticles technology</p>
--	---	--

<p>glecaprevir/ pibrentasvir</p>	<p>daclastavir</p>	<p>ravidasvir</p>
--------------------------------------	--------------------	-------------------

<p>sutezolid</p>



109 SUBLICENCES WITH 23 MANUFACTURERS – 151 ACTIVE PROJECTS

*MOU executed

● HIV ● Hepatitis C ● Tuberculosis

22

MILLION

**PATIENT-YEARS
OF
TREATMENTS***

8.05

BILLION

**DOSES
SUPPLIED BY
MPP
LICENSEES
SINCE 2012***

136

**COUNTRIES
ACCESSING
MPP
LICENSED
PRODUCTS***

\$1.06

**BILLION USD
IN SAVINGS
TO
HEALTHCAR
E SYSTEMS***

*Impact of MPP agreements until DEC 2018 by KPMG (HIV, HCV products)



medicines
patent
pool

THE EXPANSION OF MPP MANDATE
TO PATENTED ESSENTIAL MEDICINES:
PARTNERING FOR A BRIGHTER FUTURE


The MPP conducted a feasibility study to:
Assess the public health need for, feasibility and potential public health impact of, expanding its mandate to patented essential medicines in other therapeutic areas.



Background:

In 2016, organisations such as the WHO and the Lancet Commission on Essential Medicines Policies recommended **expansion of the MPP's patent pooling model to all patented essential medicines.**

Assessment funded by:

 Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Agency for Development
and Cooperation SDC



There is a public health need for sustainable access to new affordable patented medicines beyond HIV, hepatitis C and tuberculosis in low- and middle-income countries*

Accelerating access to selected medicines in **cardiovascular disease, diabetes** and **cancer** could contribute to improving public health outcomes and reducing morbidity and mortality.

The MPP could play an important role in addressing antimicrobial resistance by facilitating access to, and good stewardship of, new antibiotics.

MPP ENABLING ACCESS

“The MPP continues to be the central independent driver of access-oriented licensing in the pharmaceutical industry. Licences agreed via the MPP include the majority of the access-oriented terms and conditions looked for by the Index.”

Access to Medicines Index - 20 November 2018

“It is a welcome and significant step forward toward improving access to affordable medicines and this is why we strongly advocated for the expansion of the MPP’s mandate.”

Dr. Mariângela Simão, WHO Assistant Director-General - 24 May 2018

“We support the expansion of the Medicines Patent Pool, in their work to improve access for all to safe, effective, quality, affordable and essential health products.”

G7 Health Ministers’ Declaration - 16 May 2019



Licence management to monitor compliance and prevent market leakage



Strict quality assurance policies



Ensuring global presence or impact



Compatibility with other access policies and strategies

Flexibility to combine different medicines & develop **fixed-dose combinations** where appropriate



Allow development of innovative formulations (e.g. paediatrics)



Transparent: terms of licences published



Non-exclusive to encourage competition



DIRECT SUPPORT TO LICENSORS

MPP offers tangible actions and services, **namely human labour hours** in management of licensees and information provision.

INCREASED KNOWLEDGE AND PRIORITISED STATUS

Complimentary **insight into disease areas where the originator presence is absent or reduced**. The MPP works with the WHO and other United Nations agencies, and, NGOs to know and share what's next.

REPUTATIONAL IMPACT

There is increasing public pressure on companies to provide access, e.g. through the **Access to Medicines Index** which rates licences with MPP very highly.

SUPPORT TO PARTNERS

DIRECT SUPPORT TO LICENSEES

DIRECT SUPPORT TO LICENSORS



Contractual obligations
(licensee → licensor)
enforcement



Quarterly updates
to licensors



Diversion monitoring



Trade dress oversight

Quarterly face-to-face meetings
with licensees



In-country filing, approvals, and sales analyses



Technical and regulatory product development support




Market analysis



The MPP HIV, TB and hepatitis C activities are funded by:



MPP expansion into patented essential medicines is undertaken with the financial support from:



THANK YOU

